Table 6 Overall weighted preference value (WPV) scores, individual preference value scores, relative weights, costs and cost per unit of value
Lower level | Aflibercept + FOLFIRI | Cetuximab | Panitumumab | Higher Level | Relative Weights | |
|---|---|---|---|---|---|---|
Overall WPV score | 0.0 | 14.4 | 45.7 | 42.3 | 100.0 | 100 |
Overall survival | 0.0 | 83.9 | 44.4 | 48.9 | 100.0 | 29 |
HRQoL | 0.0 | 15.0 | 15.0 | 15.0 | 100.0 | 13 |
Progression free survival | 0.0 | 90.3 | 51.4 | 55.6 | 100.0 | 5 |
Grade 4 AEs | 0.0 | −117.9 | 50.0 | 30.0 | 100.0 | 23 |
ATC L4 | 0.0 | 100.0 | 100.0 | 0.0 | 100.0 | 6 |
Phase 3 | 0.0 | 50.0 | 66.7 | 19.4 | 100.0 | 2 |
Marketing Authorisation | 0.0 | 100.0 | 30.0 | 0.0 | 100.0 | 3 |
Posology | 0.0 | 0.0 | 37.5 | 100.0 | 100.0 | 7 |
Medical costs impact | 0.0 | 7.0 | 50.0 | 78.9 | 100.0 | 12 |
Costs (£) | 29,400 | 18,000 | 27,000 | |||
Cost per unit of value | 2,046 | 394 | 638 |